Artal Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Artal Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$241M	Buy	154,734,327 +18,553,846	+14%	+$27M	23.89%	2
2025 Q4	$157M	Hold	136,180,481	–	–	21.91%	2
2025 Q3	$184M	Hold	136,180,481	–	–	24.25%	2
2025 Q2	$129M	Hold	136,180,481	–	–	13.91%	2
2025 Q1	$62.6M	Hold	136,180,481	–	–	7.08%	2
2024 Q4	$101M	Hold	136,180,481	–	–	8.59%	2
2024 Q3	$214M	Sell	136,180,481 -38,918,903	-22%	-$69.3M	8.98%	2
2024 Q2	$294M	Buy	175,099,384 +57,546,100	+49%	+$103M	7.5%	2
2024 Q1	$282M	Hold	117,553,284	–	–	7.19%	2
2023 Q4	$180M	Hold	117,553,284	–	–	5.98%	3
2023 Q3	$128M	Hold	117,553,284	–	–	5.49%	2
2023 Q2	$269M	Buy	117,553,284 +27,775,050	+31%	+$73.7M	8.34%	2
2023 Q1	$218M	Hold	89,778,234	–	–	12.96%	1
2022 Q4	$171M	Hold	89,778,234	–	–	9.57%	1
2022 Q3	$215M	Buy	89,778,234 +18,599,870	+26%	+$51.5M	9.2%	2
2022 Q2	$132M	Hold	71,178,364	–	–	7.07%	2
2022 Q1	$149M	Hold	71,178,364	–	–	6.23%	3
2021 Q4	$280M	Hold	71,178,364	–	–	7.61%	1
2021 Q3	$342M	Hold	71,178,364	–	–	7.66%	1
2021 Q2	$327M	Hold	71,178,364	–	–	6.63%	2
2021 Q1	$418M	Hold	71,178,364	–	–	7.38%	2
2020 Q4	$243M	Buy	71,178,364 +10,937,500	+18%	+$20.9M	5.23%	4
2020 Q3	$86.7M	Hold	60,240,864	–	–	2.11%	11
2020 Q2	$120M	Hold	60,240,864	–	–	3.36%	7
2020 Q1	$117M	Hold	60,240,864	–	–	4.96%	5
2019 Q4	$250M	Hold	60,240,864	–	–	9.66%	2
2019 Q3	$181M	Hold	60,240,864	–	–	7.27%	2
2019 Q2	$379M	Hold	60,240,864	–	–	15.32%	1
2019 Q1	$335M	Hold	60,240,864	–	–	13.68%	1
2018 Q4	$400M	Hold	60,240,864	–	–	14.82%	2
2018 Q3	$643M	Hold	60,240,864	–	–	16.72%	2
2018 Q2	$723M	Buy	60,240,864 +1,966,214	+3%	+$20.1M	15.36%	2
2018 Q1	$499M	Hold	58,274,650	–	–	6.25%	3
2017 Q4	$576M	Buy	58,274,650 +756,673	+1%	+$7.86M	8.68%	3
2017 Q3	$707M	Hold	57,517,977	–	–	12.18%	3
2017 Q2	$946M	Hold	57,517,977	–	–	16.53%	3
2017 Q1	$825M	Hold	57,517,977	–	–	18.31%	2
2016 Q4	$795M	Hold	57,517,977	–	–	17.66%	2
2016 Q3	$1.04B	Hold	57,517,977	–	–	20.58%	2
2016 Q2	$825M	Hold	57,517,977	–	–	17.04%	2
2016 Q1	$687M	Hold	57,517,977	–	–	13.41%	2
2015 Q4	$766M	Sell	57,517,977 -1	-0%	-$12	14.37%	2
2015 Q3	$618M	Hold	57,517,978	–	–	13.8%	2
2015 Q2	$463M	Sell	57,517,978 -3	-0%	-$22	19.93%	1
2015 Q1	$378M	Hold	57,517,981	–	–	17.5%	1
2014 Q4	$366M	Buy	57,517,981 +21,321,962	+59%	+$172M	12.86%	2
2014 Q3	$357M	Hold	36,196,019	–	–	13.15%	2
2014 Q2	$408M	Hold	36,196,019	–	–	16.49%	2
2014 Q1	$438M	Hold	36,196,019	–	–	15.87%	2
2013 Q4	$456M	Hold	36,196,019	–	–	16.36%	2
2013 Q3	$603M	Hold	36,196,019	–	–	19.63%	2
2013 Q2	$550M	Buy	+36,196,019	New	+$550M	17.3%	2

Other funds holding LXRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Artal Group's LXRX Position: Q1 2026 in Review

Artal Group increased its Lexicon Pharmaceuticals (LXRX) stake by 14% in Q1 2026, buying an estimated $27M and bringing the position to 154,734,327 shares worth $241M. The position accounts for 23.89% of the portfolio, ranked #2.

Artal Group first reported a position in LXRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.04B in Q3 2016. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

Artal Group held 154,734,327 shares of Lexicon Pharmaceuticals worth $241M as of Q1 2026.
Artal Group bought 18,553,846 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $27M.
Lexicon Pharmaceuticals made up 23.89% of Artal Group's portfolio in Q1 2026, its #2 holding.
Artal Group first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Artal Group's Lexicon Pharmaceuticals position peaked at $1.04B in Q3 2016.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Artal Group's 13F filing for Q1 2026, filed 14 May 2026.